Effect of cisplatin on proteasome activity

J Inorg Biochem. 2015 Dec:153:253-258. doi: 10.1016/j.jinorgbio.2015.08.027. Epub 2015 Sep 4.

Abstract

Cisplatin is a widely used chemotherapy drug which exerts cytotoxic activity by affecting both nuclear and cytosolic pathways. Herewith, we report, for the first time, that cisplatin inhibits proteasome activity in vitro. Cisplatin induces a dose dependent inhibition of the three enzymatic activities of proteasome (i.e., the chymotrypsin-like activity, the trypsin-like activity and the caspase-like activity). Moreover, cisplatin administration to neuroblastoma cells brings about a fast loss of proteasome particle activity, which is followed by a de novo synthesis of proteasome. Lastly, we report that the simultaneous administration of lactacystin and cisplatin enhances the cytotoxicity of cisplatin alone. The overall bulk of data opens to an intriguing scenario, concerning the biological effects of cisplatin in the control of cellular life, which goes beyond the well established genotoxic effect.

Keywords: Cisplatin; Lactacystin; Neuroblastoma,; Proteasome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / analogs & derivatives
  • Acetylcysteine / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Drug Synergism
  • Humans
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors / pharmacology*
  • Ubiquitination

Substances

  • Antineoplastic Agents
  • Cysteine Proteinase Inhibitors
  • Proteasome Inhibitors
  • lactacystin
  • Proteasome Endopeptidase Complex
  • Cisplatin
  • Acetylcysteine